Company Profile
Hubei Biocause Heilen Pharmaceutical provides the pharmaceutical, chemical, and new energy fuel businesses in China and globally. It is involved in the R&D, production, and sales of chemical raw materials and preparations; and provision of contract R&D, and production services, as well as raw material products
Including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and preparations.
Additionally, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates. Its portfolio also includes antipyretic and analgesic, cardiovascular and anti-infective preparations, and chemicals and formulations. Founded in 1995, Hubei Biocause Heilen Pharmaceutical is based in Jingmen, China.